Label Change Helps Remove Barriers to Broader Use of Epcoritamab in DLBCL, Sharman Says

Why It Matters

Outpatient administration lowers costs, improves patient quality of life, and enables broader adoption of bispecific antibodies in community settings, accelerating treatment access for DLBCL patients.

Key Takeaways

• FDA now permits outpatient first full epcoritamab dose
• EPCORE NHL‑6: 81 of 88 patients treated outpatient
• CRS occurred in 40%; 13.6% required hospitalization
• Overall response rate 62%; complete responses 42.4%
• Outpatient option cuts costs and expands community oncology access

Pulse Analysis

Epcoritamab, marketed as Epkinly, is a CD3 × CD20 bispecific T‑cell engager approved for relapsed/refractory diffuse large B‑cell lymphoma (DLBCL) after at least two prior lines. Historically, the first full 48‑mg dose on day 15 of cycle 1 required inpatient admission, limiting use to larger centers with hospital formularies. The FDA’s April 1 label revision, prompted by interim findings from the EPCORE NHL‑6 trial, now authorizes physicians to decide between inpatient monitoring or outpatient observation, reflecting real‑world safety data and easing logistical constraints.

The EPCORE NHL‑6 study enrolled 92 patients across academic and community sites, with 81 of 88 receiving the full dose outpatient. While 40.2% experienced CRS—mostly grade 1‑2—and 7.6% developed mild‑to‑moderate ICANS, only 13.6% of outpatients required hospitalization for CRS. Importantly, all adverse events resolved without discontinuing therapy, and efficacy remained robust: a 62% overall response rate and 42.4% complete response rate matched earlier trial outcomes. These results demonstrate that with proper monitoring protocols, the safety profile of epcoritamab is compatible with outpatient care, a critical insight for scaling bispecific antibody delivery.

For managed‑care stakeholders, the label change translates into tangible financial and operational benefits. Outpatient administration reduces hospital stay costs, streamlines prior‑authorization workflows, and expands the pool of physicians able to offer the therapy, especially in community oncology practices lacking hospital formularies. As bispecifics move earlier in treatment algorithms for both lymphoma and multiple myeloma, the ability to deliver them outside the hospital will be a key differentiator for health systems seeking to meet rising demand while maintaining high‑quality, patient‑centered care.